Dr. Zdenek Hel

Department of Pathology

University Of Alabama at Birmingham, USA



1997 Ph.D., McGill University, Canada

1990 M.Sc., Charles University, Czech Republic

Publications (selected)

  1. Hel, Z., Skamene, E., and D. Radzioch. 1996. Two distinct regions in the 3'-UTR of tumor necrosis factor-α mRNA form complexes with macrophage proteins.Mol. Cell. Biol.16:5579-5590.
  2. Hel, Z., DiMarco, S., and D. Radzioch. 1998. Characterization of the RNA-binding proteins forming complexes with a novel putative regulatory region in the 3'-UTR of TNF-α mRNA.Nuc. Acid Res.26:2803-2812.
  3. Olivier, M., Cook, P., Desanctis, J.,Hel, Z., Wojciechowski, W., Reiner, N.E., Skamene, E., and D. Radzioch.1998. Phenotypic difference between Bcg(r) and Bcg(s) macrophages is related to differences in protein-kinase-C-dependent signalling.Eur. J. Biochem.251:734-743.
  4. Hel, Z., Venzon,D., Poudyal, M., Tsai, W.P., Giuliani, L., Woodward, R., Chougnet, C., Shearer, G., Altman, J., Watkins,D., Bischofberger, N., Abimuku, A., Markham, P., Tattaglia, J., and Franchini, G. 2000. Viremia control following structured treatment interruption and therapeutic immunization of SIV251 -infected macaques.Nature Med.6:1140-6.
  5. DiMarco, S.,Hel, Z., Lachance, C., Furneaux, H., and D. Radzioch. 2001. Polymorphism in the 3'-untranslated region of TNF-α mRNA impairs binding of the post-transcriptional regulatory protein HuR to TNFalpha mRNA.Nucleic Acids Res.29:863-71.
  6. Stevceva, L., Tryniszewska, E.,Hel, Z., Nacsa, J., Kelsall, B., Washington-Parks, R., and G. Franchini. 2001. Differences in time of virus appearance in the blood and virus-specific immune responses in intravenous and intrarectal primary SIVmac251 infection of rhesus macaques; a pilot study.BMC Infect. Dis.1:9.
  7. Hel, Z., Nacsa, J., Kelsall, B., Tsai, W.P., Letvin, N., Parks, R.W., Tryniszewska, E., Picker, L., Lewis, M.G., Edghill-Smith, Y., Moniuszko, M., Pal, R., Stevceva, L., Altman, J.D., Allen, T.M., Watkins, D., Torres, J.V., Berzofsky, J.A., Belyakov, I.M., Strober, W., and G. Franchini. 2001. Impairment of Gag-Specific CD8(+) T-Cell function in mucosal and systemic compartments of Simian immunodeficiency virus mac251- and Simian-human immunodeficiency virus KU2-infected macaques.J. Virol.75:11483-95.
  8. Belyakov, I.M.,Hel, Z., Kelsall, B., Kuznetsov, V.A., Ahlers, J.D., Nacsa, J., Watkins, D.I., Allen, T.M., Sette, A., Altman, J., Woodward, R., Markham, P.D., Clements, J.D., Franchini, G., Strober, W., and J. A. Berzofsky. 2001. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques.Nature Med.7:1320-6.
  9. Hel, Z., Tsai, W.P., Thornton, A., Nacsa, J., Giuliani, L., Tryniszewska, E., Poudyal, M., Venzon, D., Wang, X., Altman, J., Watkins, D.I., Lu, W., von Gegerfelt, A., Felber, B.K., Tartaglia, J., Pavlakis, G.N., and G. Franchini. 2001. Potentiation of Simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen.J. Immunol.167: 7180-7191.
  10. Pal, R., Venzon, D., Letvin, N.L., Santra, S., Montefiori, D.C., Miller, N.R., Tryniszewska, E., Lewis, M.G., VanCott, T.C., Hirsch, V., Woodward, R., Gibson, A., Grace, M., Dobratz, E., Markham, P.D.,Hel, Z., Nacsa, J., Klein, M., Tartaglia, J., and G. Franchini. 2002. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay Simian immunodeficiency virus SIVmac-induced immunodeficiency.J. Virol.76: 292-302.
  11. Stevceva, L., Kelsall, B., Nacsa, J., Moniuszko, M.,Hel, Z., Tryniszewska, E., and G. Franchini. 2002. Cervicovaginal lamina propria lymphocytes: Phenotypic characterization and their importance in cytotoxic T-lymphocyte responses to Simian immunodeficiency virus SIV(mac251).J. Virol.76: 9-18.
  12. Hel, Z., Johnson, J.M., Tryniszewska, E., Tsai, W.P., Harrod, R., Fullen, J., Tartaglia, J., and G. Franchini. 2002. A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccine.Vaccine20:3171-3186.
  13. Hel, Z. Nacsa,J., Tryniszewska, E., Tsai, W.P., Washington-Parks, R., Montefiori, D.C., Felber, B.K., Pavlakis, G.N., J., and G. Franchini. 2002. Containment of SIV infection in Tartaglia, vaccinated macaques: Correlation with the magnitude of virus-specific pre- and post-challenge CD4+ and CD8+ T-cell responses.J. Immunol.169:4778-4787.
  14. Hel, Z., Nacsa, J., Tsai, W.P., Thornton, A., Giuliani, L., Tartaglia, J., and G. Franchini.2002. Equivalent immunogenicity of the highly attenuated poxvirus-based ALVAC-SIV and NYVAC-SIV vaccine candidates in SIVmac251-infected macaques.Virology304:125-134.
  15. Tryniszewska, E., Nacsa, J., Lewis, M.G., Silvera, P., Venzon, D.,Hel, Z., Washington Parks, R., Maniuszko, M., Tartaglia, J., Smith, K.A., and G. Franchini. 2002. Vaccination of macaques with long standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy.J. Immunol.169:5347-5357.
  16. Hel, Z., Tryniszewska, E., Johnson, J.M., Harrod, R., Fullen, J., Kalyanaraman, V.S., Altman, J.D., McNally, J., Kaprova, T., Felber, B.K., Tartaglia, J., and G. Franchini. 2002. Design and in vivo immunogenicity of a polyvalent vaccine based on SIVmac regulatory genes.DNA Cell. Biol. 21:619-626.
  17. Franchini, G., Nacsa, J.,Hel, Z., and E. Tryniszewska. 2002. Immune intervention strategies for HIV-1 infection of humans in the SIV macaque model.Vaccine 20 Suppl 4:A52-60.
  18. Garnon, J., Lachance, C., Di Marco, S., Hel, Z., Marion, D., Ruiz, M.C., Newkirk, M.M., Khandjian, E.W., and D. Radzioch. 2005. Fragile X-related proteinFXR1P regulates proinflammatory cytokine tumor necrosis factor expression at the posttranscriptional level. J. Biol. Chem.280:5750-63.
  19. Hel, Z., Tsai, W.-P., Tryniszewska, E., Nacsa, J., Markham, P.D., Lewis, M.G., Pavlakis, G.N., Felber, B.K., Tartaglia, J., and Franchini, G. 2006. Improved vaccine protection from simian AIDS by the addition of nonstructural SIV genes. J. Immunol. 176:85-96.

Profile Details